| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e14d6eb6e2b529693a4fd5c5238b4e4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-6555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-22 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-655
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-18 |
| filingDate |
2000-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a75b9aaaee5e4ecaebf657f832ff145a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aba9bac7e89b187bc16424ac82fb9844
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bbee4e890ad06d78ff20f7134875092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4ec6982a9ceac898e691e6c83750f09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60a2b4b35e9000e69476bd576ff4989b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faed15e7ccb71f67769d2e5a9273781b |
| publicationDate |
2002-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6407059-B1 |
| titleOfInvention |
Conformationally constrained backbone cyclized peptide analogs |
| abstract |
Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are Nalpha(omega-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these Nalpha(omega-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005267017-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2133362-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11261215-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019058365-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10662225-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004019866-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7439226-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022003673-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017212477-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020170249-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2671891-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005130883-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008242600-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011024175-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015087334-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013111129-A1 |
| priorityDate |
1994-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |